ArticleAmerican journal of clinical and experimental immunology2025
DPT has potential to be a prognostic biomarker and its correlation with immune infiltrates in prostate cancer.
Article in American journal of clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PRAD) poses a significant threat to male health. The tumor microenvironment (TME) plays a crucial role in its development process, yet the regulatory significance of specific extracellular matrix proteins such as Dermatopontin (DPT) in PRAD remains poorly understood.
methodsA total of 534 PRAD transcriptome profiles were retrieved from The Cancer Genome Atlas (TCGA) database. CIBERSORT and ESTIMATE computational methods were used to quantify the presence of immune and stromal components. Differentially expressed genes (DEGs) were identified based on ImmuneScore and StromalScore, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genomes (KEGG) pathway enrichment analyses. DPT expression was analyzed in relation to overall survival, TNM staging, immune-related pathways using Gene Set Enrichment Analysis (GSEA), and tumor-infiltrating immune cells (TICs).
resultsA total of 454 DEGs overlapping between high ImmuneScore and StromalScore groups were enriched in immune-related processes and pathways. DPT expression was positively correlated with the survival of PRAD patients, especially the N Stage of PRAD. GSEA revealed that high DPT expression correlated with immune-related activities such as allograft rejection, apical junction, complement, and epithelial mesenchymal transition while low DPT expression was correlated with metabolic pathways such as E2f targets, G2m checkpoint, mitotic spindle, and mitorc1 signaling. Analysis of TICs showed that DPT expression was positively correlated with resting mast cells and neutrophils. Conversely, regulatory T cells, M1 macrophages, M2 macrophages, and resting dendritic cells exhibited negative correlations with DPT expression.
conclusionsDPT may serve as a novel prognostic biomarker in PRAD, potentially affecting the survival of PRAD patients by regulating the immune environment of TME. These findings provide new insights into the immunomodulatory role of DPT and its potential as a therapeutic target for PRAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.